The Purpose of this conference is to provide attendees with access to cutting edge clinical and basic science research in the fields of clinical nephrology and transplantation, renal physiology and pharmacology, and renal pathology and immunology.
- Physicians
- Physicians Assistants
- Nurse/Nurse Practitioners
- Medical Students
At the conclusion of this activity, I will be able to:
Learn the contribution for soluable epoxide hydrolase and epoxyeicosatrienoic acids (EETs) in kidney disease.
Explore therapeutic potential for SEHI and EET analogs to combat kidney diseases.
Discuss collaborative projects to accelerate SEHI and EET analogs to treat kidney diseases in humans.
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following person(s):
Name | Company | Role |
John Imig, PhD | IP EET Analogs | Inventor |
IP SEHI | Inventor | |
Diplos Therapeutics | Owner |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.